Status:
TERMINATED
Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection
Lead Sponsor:
Avexa
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Apricitabine is a new NRTI which is active against drug-resistant HIV. NRTIs are often included as part of patients' treatment, but many HIV-infected patients develop resistance to commonly used NRTIs...
Detailed Description
ATC has potent antiviral activity both in vitro (against wild-type HIV-1 and HIV-1 with mutations in reverse transcriptase that confer resistance to NRTIs), and in clinical studies in both treatment-n...
Eligibility Criteria
Inclusion
- HIV-1 positive with M184V/I mutation in reverse transcriptase;
- 18 years of age or older;
- Currently taking lamivudine (3TC) or emtricitabine (FTC)
Exclusion
- Female patients who are pregnant or breastfeeding;
- Current hepatitis B virus (HBV) infection;
- Current treatment for hepatitis C virus infection;
- Renal function not adequate
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
239 Patients enrolled
Trial Details
Trial ID
NCT00612898
Start Date
February 1 2008
End Date
January 1 2010
Last Update
January 23 2012
Active Locations (100)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB, 845 19th St South, South Beville Biomedical Research Building
Birmingham, Alabama, United States, 35294-2170
2
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-2170
3
Southwest Center for HIV/AIDS
Phoenix, Arizona, United States, 85006
4
Living Hope Clinical Foundation, Inc
Long Beach, California, United States, 90813